These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 38523673)
1. The role of proteasomes in tumorigenesis. Zhou X; Xu R; Wu Y; Zhou L; Xiang T Genes Dis; 2024 Jul; 11(4):101070. PubMed ID: 38523673 [TBL] [Abstract][Full Text] [Related]
2. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target]. Reboud-Ravaux M Biol Aujourdhui; 2021; 215(1-2):1-23. PubMed ID: 34397372 [TBL] [Abstract][Full Text] [Related]
3. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967 [TBL] [Abstract][Full Text] [Related]
4. Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes. Mittenberg AG; Kuzyk VO; Shabelnikov SV; Gorbach DP; Shatrova AN; Fedorova OA; Barlev NA Cell Cycle; 2018; 17(14):1745-1756. PubMed ID: 30009671 [TBL] [Abstract][Full Text] [Related]
6. Efficiency of the four proteasome subtypes to degrade ubiquitinated or oxidized proteins. Abi Habib J; De Plaen E; Stroobant V; Zivkovic D; Bousquet MP; Guillaume B; Wahni K; Messens J; Busse A; Vigneron N; Van den Eynde BJ Sci Rep; 2020 Sep; 10(1):15765. PubMed ID: 32978409 [TBL] [Abstract][Full Text] [Related]
7. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288 [TBL] [Abstract][Full Text] [Related]
8. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325 [TBL] [Abstract][Full Text] [Related]
9. Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer. Rohondia SO; Ahmed ZSO; Dou QP Curr Cancer Drug Targets; 2020; 20(6):392-409. PubMed ID: 32101123 [TBL] [Abstract][Full Text] [Related]
10. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit. Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995 [TBL] [Abstract][Full Text] [Related]
12. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957 [TBL] [Abstract][Full Text] [Related]
14. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826 [TBL] [Abstract][Full Text] [Related]
15. Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes. Grover A; Shandilya A; Bisaria VS; Sundar D BMC Genomics; 2010 Dec; 11 Suppl 4(Suppl 4):S15. PubMed ID: 21143798 [TBL] [Abstract][Full Text] [Related]
16. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910 [TBL] [Abstract][Full Text] [Related]
17. Reduction in ATP levels triggers immunoproteasome activation by the 11S (PA28) regulator during early antiviral response mediated by IFNβ in mouse pancreatic β-cells. Freudenburg W; Gautam M; Chakraborty P; James J; Richards J; Salvatori AS; Baldwin A; Schriewer J; Buller RM; Corbett JA; Skowyra D PLoS One; 2013; 8(2):e52408. PubMed ID: 23383295 [TBL] [Abstract][Full Text] [Related]
18. Proteasomes of the yeast S. cerevisiae: genes, structure and functions. Hilt W; Wolf DH Mol Biol Rep; 1995; 21(1):3-10. PubMed ID: 7565661 [TBL] [Abstract][Full Text] [Related]
19. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819 [TBL] [Abstract][Full Text] [Related]
20. Effect of noncompetitive proteasome inhibition on bortezomib resistance. Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]